Iron May Reduce Heart Failure Risk in CKD, but More Trials Needed
HCPLive
FEBRUARY 12, 2025
Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
HCPLive
FEBRUARY 12, 2025
Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.
HCPLive
MAY 20, 2024
A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.
Medical Xpress - Cardiology
DECEMBER 19, 2023
Heart failure is causally associated with chronic kidney disease (CKD), according to a study published online Dec. 11 in PLOS ONE.
DAIC
APRIL 30, 2024
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.
DAIC
JULY 30, 2024
This study by Fujita Health University researchers revealed that kidney function, considered in terms of estimated glomerular filtration rate (eGFR), can be used as a predictor for SCD in patients with congestive heart failure. During the follow-up period, 198 of these patients suffered from SCD.
Science Daily - Heart Disease
FEBRUARY 14, 2025
New research shows sotagliflozin is the only drug in its class to demonstrate these results.
Circulation
SEPTEMBER 10, 2024
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations in serum creatinine, kidney dysfunction encompasses inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions.
Cardiovascular Diabetology
JUNE 14, 2024
Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
HCPLive
SEPTEMBER 26, 2024
Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. Abstract Aims Angiotensin receptorneprilysin inhibitor (ARNI) has played an increasingly important role in the management of heart failure (HF).
Science Daily - Heart Disease
DECEMBER 16, 2024
atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant complications associated with this condition include ischemic stroke, heart failure, myocardial infarction, chronic kidney disease, dementia and mortality.
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
European Journal of Heart Failure
NOVEMBER 26, 2024
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
HCPLive
NOVEMBER 11, 2024
Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.
CardiacWire
OCTOBER 6, 2024
Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. The post Finerenone’s Early Heart Failure Impact appeared first on Cardiac Wire. And with a new drug, knowing which patients to target is a good way to start.
Frontiers in Cardiovascular Medicine
DECEMBER 18, 2023
Chronic kidney disease coexists in up to 40%–50% of patients with chronic heart failure cases. There are guidelines for patients with heart failure and chronic kidney disease separately, but they do not specifically address patients with concomitant heart failure and kidney disease.
European Journal of Heart Failure
OCTOBER 18, 2023
Mineralocorticoid receptor antagonist (MRA) use in severe chronic kidney disease and heart failure with reduced ejection fraction (HFrEF). Methods and results We analysed patients with HFrEF (ejection fraction <40%), not on dialysis, from the Swedish Heart Failure Registry.
DAIC
APRIL 6, 2024
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.
Circulation
NOVEMBER 11, 2024
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). However, the association of former and current smoking status (vs.
American College of Cardiology
FEBRUARY 5, 2024
Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.
Cardiometabolic Health Congress
NOVEMBER 14, 2024
Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,
Open Heart
OCTOBER 31, 2024
Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers.
European Journal of Heart Failure
JANUARY 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. a If patients were receiving both types of diuretics at baseline, they were included in both subgroups. Patients were analysed by baseline diuretic use (yes/no) and type of diuretic (loop or thiazide).
Cardiovascular Diabetology
AUGUST 6, 2024
Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Furthermore, compared with other GLD, the use of cardioprotective GLD was more common in patients with a less frequent history of heart failure (5.0%
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
Journal of the American Heart Association
DECEMBER 24, 2024
Journal of the American Heart Association, Ahead of Print. The index date was the first CKD stage 3b/4 diagnosis with 1 hyperkalemia diagnosis and 1 serum potassium >5.0 mmol/L in the preceding 12 months (baseline) for patients with hyperkalemia and a randomly selected CKD stage 3b/4 diagnosis for controls.
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.
Open Heart
APRIL 24, 2024
Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). Treatment is complicated by side effects and comorbidities.
Circulation
JANUARY 27, 2025
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Open Heart
JUNE 1, 2022
Objectives We aim to assess the association of cardiovascular medications with outcomes of patients referred to the diagnostic heart failure (HF) clinic with symptoms or signs of possible HF, raised N-terminal pro-brain-type natriuretic peptide (NT-proBNP) but no evidence of HF on transthoracic echocardiography (TTE).
Frontiers in Cardiovascular Medicine
JANUARY 5, 2025
IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) 7,054.0)] pg/ml.
Open Heart
JANUARY 4, 2025
Background Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum of phenotypes with associated disparate outcomes. AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) AKI criteria.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
Journal of the American Heart Association
JANUARY 12, 2024
ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovascular disease. Elevated urinary albumin excretion indicates kidney damage and systemic vascular disease, including myocardial capillary disease and arterial stiffness.
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001).
European Journal of Heart Failure
JANUARY 20, 2025
The predictive ability of different risk scores developed and validated to predict the risk of mortality in patients with heart failure in the HELP-HF cohort is reported and compared based on their areas under the curve.
Circulation
NOVEMBER 11, 2024
A 35-year-old gravida 1, para 0 with biventricular heart failure (LVEF 25%), nonischemic cardiomyopathy, history stroke, history of left ventricular thrombus, class III obesity, and chronic kidney disease who had been followed by Cardio-Obstetrics throughout her pregnancy presented at 34 weeks gestation for planned induction of labor.
European Journal of Heart Failure
DECEMBER 22, 2023
ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heart failure (HF) population across the ejection fraction (EF). 1.65), chronic kidney disease (HR 1.37, 95%CI 1.34-1.41),
Journal of the American Heart Association
JANUARY 31, 2024
Journal of the American Heart Association, Ahead of Print. BackgroundPatients with heart failure and chronic kidney disease (CKD) may have an increased risk of death from causes competing with arrhythmic death, which could have implications for the efficacy of implantable cardioverter‐defibrillators (ICDs).
The American Journal of Cardiology
OCTOBER 5, 2024
Publication date: Available online 5 October 2024 Source: The American Journal of Cardiology Author(s): Meghana Iyer, Khaled Ziada, Leslie Cho, Jacqueline Tamis-Holland, Umesh Khot, Amar Krishnaswamy, Rishi Puri, Samir Kapadia, Grant W Reed
Circulation
NOVEMBER 11, 2024
Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.
Heart BMJ
OCTOBER 10, 2024
The association between AF and various conditions—including hypertension, heart failure, sleep apnoea and chronic kidney disease—is well-described, highlighting that AF is often a multisystem disorder. 2 Before the.
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Empagliflozin reduced the risk of lower respiratory tract infections. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content